Longeveron Inc (LGVN) Stock Price, Quote & News

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 470 2550

Website: longeveron.com

Address:

Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States

TuJaro Jun. 30 at 2:39 PM

$LGVN isn't next year that big news will come out ? I think this new guy will do some good as his record shows.

0 · Reply

Ueberschlaefer Jun. 30 at 12:41 PM

$LGVN out. after watching yet another Alz drug fail today and with $AVXL lining up for the Grim Reaper, i'm out. no more Alz stocks for me. shkreli calls them, retail still chases them. fun to watch the wreckage from the sidelines.

3 · Reply

Ueberschlaefer Jun. 30 at 12:08 AM

$LGVN will need to raise money by Q3. given their costs and the low price of the stock, i expect it to be a big dilution. this will force the price down, possibly below minimum bid. i don't really see much going for this stock for the next couple of years. there's a high probability of failure and they've no partners and nothing doing in that area. it's an unfortunately a very binary stock; total win or total failure. i started losing my appetite for it after the board member dumped 10%; this information shows up unprompted now in LLMs, so other potential investors will be wary of the company.

0 · Reply

Finnisher2M Jun. 28 at 11:18 AM

$LGVN 👍

0 · Reply

smojo2 Jun. 27 at 2:16 PM

$LGVN Adding. I think still has a shot to go up

0 · Reply

terrapin22 Jun. 27 at 3:42 AM

$LGVN in this prospect

0 · Reply

Ueberschlaefer Jun. 27 at 12:55 AM

$LGVN catalyst roadmap going forward.

0 · Reply

Dorps332 Jun. 26 at 1:16 PM

$LGVN time to roll up your sleeves management and get this done. We need that partnership months ago. Obviously bigger pharma doesn’t believe so we had to bring new blood into get it done. Let’s go Mr Powell make it happen

1 · Reply

Dorps332 Jun. 26 at 1:14 PM

$LGVN https://investors.longeveron.com/news/News/news-details/2025/Longeveron-Appoints-Than-Powell-as-Chief-Business-Officer/default.aspx

0 · Reply

Dailyfollower Jun. 26 at 9:17 AM

$LGVN 👎$CREG👆👌

0 · Reply

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 24, 2025, 6:30 AM EDT - 6 days ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 9, 2025, 9:15 AM EDT - 21 days ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 20, 2025, 9:15 AM EDT - 5 weeks ago

Longeveron® to Attend BIO International Convention 2025

May 12, 2025, 7:15 AM EDT - 7 weeks ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 9, 2025, 5:31 PM EDT - 7 weeks ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 7 weeks ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025, 8:30 AM EDT - 2 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 11, 2025, 8:30 AM EDT - 3 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 5, 2025, 9:25 AM EST - 4 months ago

Longeveron® to Present at the 37th Annual Roth Conference

Feb 28, 2025, 7:04 PM EST - 4 months ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 4:04 PM EST - 4 months ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 18, 2025, 9:25 AM EST - 4 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Dec 18, 2024, 9:10 AM EST - 6 months ago

Longeveron to Present at Biotech Showcase 2025

Dec 2, 2024, 9:05 AM EST - 7 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Nov 12, 2024, 10:37 PM EST - 8 months ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 9:05 AM EST - 8 months ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 4, 2024, 4:05 PM EST - 8 months ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 29, 2024, 10:00 AM EDT - 8 months ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 27, 2024, 3:10 PM EDT - 8 months ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 14, 2024, 9:05 AM EDT - 9 months ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 9, 2024, 9:05 AM EDT - 9 months ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 7, 2024, 9:05 AM EDT - 9 months ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 2, 2024, 9:05 AM EDT - 9 months ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:05 AM EDT - 9 months ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Aug 26, 2024, 4:05 PM EDT - 10 months ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 7:58 PM EDT - 11 months ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 9, 2024, 9:00 AM EDT - 1 year ago

Neha Motwani Elected to Longeveron® Board of Directors

Jul 8, 2024, 9:00 AM EDT - 1 year ago

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Jun 18, 2024, 4:48 PM EDT - 1 year ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Jun 17, 2024, 9:00 AM EDT - 1 year ago

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Jun 17, 2024, 8:38 AM EDT - 1 year ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Jun 13, 2024, 9:45 AM EDT - 1 year ago

Why has Longeveron stock tripled in two days?

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

May 28, 2024, 8:05 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2024

May 17, 2024, 11:08 PM EDT - 1 year ago

Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Board of Directors Planned Transitions

May 2, 2024, 8:03 AM EDT - 1 year ago

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the Planet MicroCap Showcase

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

Apr 11, 2024, 5:17 PM EDT - 1 year ago

Longeveron Announces Closing of $5.2 Million Public Offering

Apr 8, 2024, 2:15 PM EDT - 1 year ago

Longeveron Announces Pricing of $5.25 Million Public Offering

TuJaro Jun. 30 at 2:39 PM

$LGVN isn't next year that big news will come out ? I think this new guy will do some good as his record shows.

0 · Reply

Ueberschlaefer Jun. 30 at 12:41 PM

3 · Reply

Ueberschlaefer Jun. 30 at 12:08 AM

0 · Reply

Finnisher2M Jun. 28 at 11:18 AM

$LGVN 👍

0 · Reply

smojo2 Jun. 27 at 2:16 PM

$LGVN Adding. I think still has a shot to go up

0 · Reply

terrapin22 Jun. 27 at 3:42 AM

$LGVN in this prospect

0 · Reply

Ueberschlaefer Jun. 27 at 12:55 AM

$LGVN catalyst roadmap going forward.

0 · Reply

Dorps332 Jun. 26 at 1:16 PM

1 · Reply

Dorps332 Jun. 26 at 1:14 PM

$LGVN https://investors.longeveron.com/news/News/news-details/2025/Longeveron-Appoints-Than-Powell-as-Chief-Business-Officer/default.aspx

0 · Reply

Dailyfollower Jun. 26 at 9:17 AM

$LGVN 👎$CREG👆👌

0 · Reply

Dorps332 Jun. 24 at 10:14 PM

$LGVN polished turd

0 · Reply

TuJaro Jun. 24 at 7:06 PM

$LGVN let's hope they will find a partner or sponsor I have gut feeling good things are coming for this company fingers crossed

0 · Reply

TuJaro Jun. 24 at 5:52 PM

$LGVN such good news where is the volume this should be flying, let's go people!!!

1 · Reply

Dorps332 Jun. 24 at 5:03 PM

$LGVN 😂 no strength

0 · Reply

kadeee Jun. 24 at 3:41 PM

$TRIB $LGVN $ONMD

0 · Reply

ZacksSCR Jun. 24 at 3:35 PM

$LGVN Announces Pivotal Test Update https://buff.ly/wLyMhG0

0 · Reply

Ueberschlaefer Jun. 24 at 2:30 PM

$AVXL $LGVN

0 · Reply

Bigbioinvestor Jun. 24 at 2:11 PM

$LGVN Wall Street sees zero value in this company. You can tell by the 3% institutional holdings. Inter-coastal and armistice capital are the only ones that made money here shorting. The covering with their added on warrants. Management got played and now we sit here with zero money and no partnerships. It’s time for old man Soffer to drop some cash to get this to the finish line!

1 · Reply

Dorps332 Jun. 24 at 10:47 AM

$LGVN let the 12 month clock start

0 · Reply

SpartanVI Jun. 24 at 10:41 AM

$LGVN phase 2 news Watching 7am

1 · Reply

Thestocktraderhubzee Jun. 24 at 10:39 AM

WATCHLIST JUN 24 2025 $CORT Corcept Therapeutics Reveals That Catalyst Trial Meets Primary Endpoint With Improvement In HbA1c; Catalyst Trial Meets Secondary Endpoints With Reduced Body Weight And Waist Circumference $SAM SmartStop Self Storage REIT Announces The Acquisition Of A Class A Self-Storage Facility In Houston, Texas; No Terms Disclosed $KLTO Klotho Neuroscience Partners With Okinawa Longevity Experts to Explore Gene Therapy for Healthy Aging $LGVN Longeveron Completes Enrollment Of Phase 2b Clinical Trial Evaluating Investigational Cellular Therapy Laromestrocel As Potential Adjunct Treatment For Hypoplastic Left Heart Syndrome $VZ Verizon Unveils AI-Powered Customer Experience Overhaul Built On America's Fastest, Most Reliable 5G Network

0 · Reply

GreenResearchers Jun. 24 at 12:59 AM

ATER is a high-conviction setup. $14–$21 DCF value TEMU = global e-com exposure No dilution, active buyback 500%+ upside still on the table… $LITM $ACXP $LGVN $SYTA

0 · Reply

Market Cap	19.71M
Revenue (ttm)	2.39M
Net Income (ttm)	-15.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-668.20%
Debt to Equity Ratio	0.00

Volume	71,805
Avg Vol	132,948
Day's Range	N/A - N/A
Shares Out	14.93M
Stochastic %K	68%
Beta	0.22
Analysts	Strong Sell
Price Target	$8.89